Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Synlogic, Inc. (NASDAQ: SYBX).

Full DD Report for SYBX

You must become a subscriber to view this report.


Recent News from (NASDAQ: SYBX)

Synlogic Announces Third Quarter 2018 Conference Call and Webcast
Synlogic, Inc. ( Nasdaq: SYBX ), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telepho...
Source: Business Wire
Date: November, 07 2018 16:20
Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
– Data highlight the differential advantages of Synthetic Biotic approach designed to activate the local innate immune system for the potential treatment of a variety of solid tumors – – Company will webcast Investor and Analyst event at 12:30 pm ET, Saturday, Nove...
Source: Business Wire
Date: November, 06 2018 08:01
Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
- Presentations to feature key opinion leaders and expand on preclinical data from Synlogic’s first immuno-oncology candidate, accepted for presentation at SITC 2018 - - Company to webcast event, beginning at 12:30 p.m. ET on Saturday, November 10, 2018 - Synlogic, Inc. ( ...
Source: Business Wire
Date: November, 01 2018 16:05
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer
Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, effective immediately. Dr. Brennan joine...
Source: Business Wire
Date: October, 02 2018 07:00
Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare Diseases and Oncology at 11:30 am ET on Tues...
Source: Business Wire
Date: September, 25 2018 16:05
Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Aoife M. Brennan, M.B., B.Ch., to its board of directors. “Dr. Brennan has an impressive track record of success in advancing the development of numerous drug candidates throughout her career, with experience i...
Source: Business Wire
Date: September, 25 2018 07:30
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Source: SeekingAlpha
Date: September, 07 2018 16:31
Synlogic (SYBX) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by Synlogic, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 15:07
Midday Gainers / Losers (09/05/2018)
Gainers: PRQR +62% . MNKD +33% . SBOT +19% . VCEL +18% . NSU +17% . SYBX +15% . CORV +15% . VRA +15% . MVIS +14% . IGC +13% . More news on: ProQR Therapeutics, MannKind Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 12:47
Synlogic reports positive Phase 1/2a data for SYNB1618 for the management of PKU
Synlogic (NASDAQ: SYBX ) announces positive interim clinical data from the healthy volunteer (HV) arm of its ongoing Phase 1/2a study of SYNB1618 in HVs and patients with phenylketonuria (PKU). More news on: Synlogic, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 04 2018 08:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0812.8612.9713.4412.60180,198
2018-05-1710.209.9710.399.6795,504

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-119,28722,60741.0802Short
2018-12-1012,49931,66539.4726Short
2018-12-072,87511,51424.9696Cover
2018-12-062,85614,95319.0998Cover
2018-12-047,11522,83231.1624Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SYBX.


About Synlogic, Inc. (NASDAQ: SYBX)

Logo for Synlogic, Inc. (NASDAQ: SYBX)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: SYBX)

    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 15 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 15 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: May, 15 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: May, 10 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 27 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: April, 16 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: April, 12 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 06 2018
    Prospectus filed under Rule 424(b)(5)
    Filing Type: 424B5Filing Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 20 2018

     

     


    Daily Technical Chart for (NASDAQ: SYBX)

    Daily Technical Chart for (NASDAQ: SYBX)


    Stay tuned for daily updates and more on (NASDAQ: SYBX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: SYBX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SYBX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SYBX and does not buy, sell, or trade any shares of SYBX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/